Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Sickle cell pain in the emergency department
source: National Institute for Children’s Health Quality
year: 2015
summary/abstract:Sickle cell disease is characterized by unpredictable episodes of extreme pain, known as acute vaso-occlusive episodes (VOE) or pain episodes, caused when sickled red blood cells are unable to move freely through blood vessels. In addition to pain, these changes at the cellular level can also lead to organ damage, stroke and even death. Pain episodes are the most common reason for emergency department (ED) visits and hospitalizations for patients with sickle cell disease. Detailed guidelines and quality indicators for the management of pain episodes currently exist, but both pediatric and adult patients with the disease often experience prolonged periods of waiting for treatment in the emergency department and ineffective treatment of their pain.
Delays in treatment are often due to systemic factors, such as the lack of a clear treatment protocol or limited provider experience in treating sickle cell diseaserelated pain. Prolonged waits for effective pain relief can lead to unnecessary suffering, hospitalizations, chronic pain syndromes, other complications and increased health care costs.1,8,10-12 Ensuring patients receive timely, effective pain relief is one of the most important elements of delivering high quality care to individuals with sickle cell disease in the emergency department.
read more
+myBinderRelated Content
-
Acute Vaso-Occlusive pain associated with the onset of menstruation is distinct from dysmenorrhea in sickle cell dis...Acute vaso-occlusive pain episodes are t...
-
Improving Quality of Care for Sickle Cell Patients in the Pediatric Emergency DepartmentOBJECTIVE: The aim of this study was to ...
-
Don’t Be Shy About Asking to Remain in the HospitalOne of the best feelings in the world is...
-
GBT expands sickle cell disease pipeline with worldwide licensing agreement for inclacumab for the treatment of vaso...Global Blood Therapeutics, Inc...
-
Sickle cell patients in UK survey, especially those 16 to 20, voice problems with care and pain relief givenIn a survey, patients across the...
-
Crizanlizumab designated FDA breakthrough therapy for potential in vaso-occlusive crisis preventionCrizanlizumab (SEG101), Novartis‘ inve...
-
Our Healthcare System Abandons Adult Sickle Cell PatientsWhen Janoi Burgess was a child, he thoug...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.